OLX104C: Can Silencing a Gene Stop Hair Loss?
Published by AmpleLab Research
Most hair loss drugs in development work by blocking a hormone or a receptor. OLX104C works by trying to silence the gene that makes the receptor in the first place, using RNA interference, the same broad technology behind several approved drugs for other conditions, aimed here at the androgen receptor itself. It comes from OliX Pharmaceuticals, a Korean RNAi company with a wider drug pipeline, not a single-asset hair loss startup.
There is also a naming detail worth clearing up before getting into the science, because English- and Korean-language coverage of this drug has used two different codes, OLX104C and OLX72021, in ways that can look like two separate compounds if you're not reading closely. They are not. This article covers what the mechanism is, what the peer-reviewed preclinical data shows, how OliX itself distinguishes the two names, and what the Phase 1 safety data and the ongoing Phase 1b/2a trial have shown so far.
A Genuinely Different Mechanism
Among drugs that target the DHT and androgen receptor pathway specifically, there are two main approaches: reduce how much DHT gets made (finasteride and dutasteride, by inhibiting 5-alpha reductase), or block DHT from binding the androgen receptor once it's made (topical antiandrogens like clascoterone, RU58841, and KX-826, covered in our KX-826 vs RU58841 comparison). OliX's compound works on a third lever entirely: reducing how much androgen receptor protein the follicle makes at all.
The platform behind this is called cp-asiRNA, cell-penetrating asymmetric small interfering RNA, OliX's proprietary version of RNA interference (RNAi), a naturally occurring cellular process that Nobel Prize-winning research showed could be harnessed to selectively degrade a specific messenger RNA before it gets translated into protein. Applied here, the asiRNA molecule is designed to bind and destroy the mRNA that codes for the androgen receptor, so cells in the follicle produce less of the androgen receptor that DHT would otherwise act on, rather than having a working receptor that gets chemically blocked or a hormone that gets chemically suppressed.
The Peer-Reviewed Preclinical Data
Unlike some candidates on this pipeline, OliX's preclinical work for OLX104C (referred to as cp-asiAR in the paper itself) made it into a peer-reviewed journal, Molecular Pharmaceutics, in December 2022, rather than staying at the press-release stage.
In a DHT-induced androgenetic alopecia mouse model, intradermal cp-asiAR injections (0.125-0.5 mg, on days 1, 8, and 15) reduced androgen receptor mRNA and protein in the skin and produced a significantly greater increase in hair weight than vehicle control over 21 days. The 0.5 mg dose maintained more than 50% AR protein inhibition for up to three weeks after dosing. In a separate ex vivo experiment on cultured human hair follicles, cp-asiAR-treated follicles showed a lower proportion in the resting (telogen) phase and a larger mean hair bulb diameter than untreated follicles, and treatment reduced DHT-driven increases in three signalling molecules linked to follicle miniaturisation (interleukin-6, TGF-β1, and dickkopf-1). The study was funded by a Korean government medical device development grant; several authors, including OliX CEO Dong-Ki Lee, are affiliated with OliX Pharmaceuticals, with one co-author based at Asan Medical Center, Seoul.
This is a real, peer-reviewed dataset with a plausible, mechanistically coherent story: less receptor protein, less DHT signalling, less of the downstream miniaturisation signal, more hair. It is still, however, a mouse model and a short-term ex vivo human follicle culture, not a clinical trial. Mouse skin and human scalp respond differently to androgen signalling in some well-documented ways, which is exactly why a human trial is the next necessary step rather than a formality.
OLX104C and OLX72021 Are the Same Drug
This wasn't obvious from the English-language coverage alone. OliX's Western press releases through 2023-2025, the ones that announced the first human trial and its safety results, referred to the compound almost exclusively as OLX72021, without mentioning OLX104C. Read on their own, it would be reasonable to wonder whether OLX72021 was a related but distinct candidate rather than the same molecule that produced the 2021-2022 preclinical data under the OLX104C name.
OliX's own Korean-language disclosures resolve this directly. Korean biotech press coverage of the drug, which tracks the company's domestic filings closely, consistently describes it using the formula "OLX104C (물질명 OLX72021)", "OLX104C (substance name: OLX72021)". That phrasing appears identically across separate articles spanning March 2025 through September 2026, including coverage of the same Phase 1b/2a trial (Bellberry HREC submission, roughly 120-158 participants, Australia and New Zealand) that Western press releases and the ClinicalTrials.gov registration describe under the OLX72021 name alone. OLX104C is OliX's candidate/programme name; OLX72021 is the specific chemical substance code for that candidate. They are two labels for one drug, not two drugs, and OliX's own domestic disclosures use both together, even where its English-language materials have used only one.
We're flagging this explicitly because it's an easy thing to get wrong by relying on English-language sources alone, and because a reader piecing this compound's history together from press coverage in only one language could reasonably end up treating the preclinical dataset and the clinical trial as two different, unconnected programmes. They aren't.
The Phase 1 Safety Data
The first human trial, a single ascending dose study in 25 healthy men with androgenetic alopecia across three Australian sites, dosed its first participant in June 2023. Each of five cohorts of six men received a single intradermal injection across six scalp sites, with four men per cohort receiving OLX72021 and two receiving placebo, followed for 56 days.
No serious adverse events occurred, adverse event frequency did not rise with dose, and reported events were assessed as having low or no causal relationship to treatment. No clinically significant abnormalities were reported on ECG, vital signs, or laboratory testing, and physical exam abnormalities occurred only in the placebo group. This was a safety and tolerability study; the report did not disclose specific efficacy or hair-count data from this trial.
A clean single-ascending-dose safety readout is a genuinely useful result, it's the result a Phase 1 trial is designed to produce, but it answers a narrower question than "does it work." It says an injectable RNAi drug aimed at the androgen receptor didn't cause obvious harm at the doses tested in 25 men over eight weeks. Whether it grows hair is a question this trial wasn't built to answer and, per OliX's own disclosure, didn't answer.
Where It Stands Now
OliX has since moved into a combined Phase 1b/2a trial (registered as NCT07327359), larger and longer than the first study: men with mild-to-moderate androgenetic alopecia (Hamilton-Norwood grades III-V), randomised, double-blind, and placebo-controlled, with a multiple-ascending-dose Phase 1b portion followed by a larger Phase 2a efficacy portion. According to Korean press coverage of the company's own disclosures, first-patient dosing in Phase 1b began 19 December 2025, and final-patient dosing for that portion was completed 27 July 2026, across two dose cohorts given multiple intradermal injections. OliX has since expanded the Phase 2a portion to include New Zealand alongside Australia, after New Zealand's Medsafe approved the expansion, bringing total planned enrolment to around 158 across three active dose groups plus placebo, with first-patient dosing in Phase 2a targeted for the end of 2026. This is the first trial in the programme designed to generate an actual efficacy signal rather than a safety readout alone, and it had not yet reported one as of this writing.
OliX is not a single-product company built around this candidate. It's a KOSDAQ-listed Korean RNAi developer with a broader cp-asiRNA pipeline, including an FDA-cleared candidate for wet age-related macular degeneration and an ophthalmology collaboration with the French pharmaceutical company Théa Laboratoires, among other programmes.
Common Questions
What makes OLX104C's mechanism different from finasteride or topical antiandrogens?
Finasteride and dutasteride reduce how much DHT gets made; drugs like clascoterone, RU58841, and KX-826 block DHT from binding the androgen receptor once it exists. OLX104C uses RNA interference to reduce how much androgen receptor protein the follicle makes in the first place, a third mechanism distinct from either approach.
Are OLX104C and OLX72021 the same drug?
Yes. OliX's own Korean-language disclosures consistently describe the drug as "OLX104C (substance name: OLX72021)": OLX104C is the candidate name, OLX72021 the specific chemical substance code. OliX's English-language press releases about the human trials have generally used only the OLX72021 name, which is why the connection isn't obvious from Western coverage alone.
Has OLX104C/OLX72021 been shown to regrow hair in humans?
Not yet in any publicly disclosed data. The only completed human trial to date was a Phase 1 safety and tolerability study that did not report efficacy data. The current Phase 1b/2a programme is the first in the programme designed to generate an efficacy readout. Phase 1b has completed dosing and follow-up, while Phase 2a is now being expanded to New Zealand and has not yet reported efficacy data.
Is OLX104C available or close to approval?
No. It's an investigational compound in an ongoing Phase 1b/2a trial with no disclosed human efficacy data. It's not approved anywhere and not available to buy.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. OLX104C/OLX72021 is an investigational compound not approved for any use by the FDA, MHRA, Korean MFDS, or any other regulatory body, with no disclosed human efficacy data. AmpleLab products are unrelated to this compound or its developer and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.